ACRO BIOMEDICAL CO., LTD.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $658.5K | $1.2M | $688.0K | $193.5K | $8.0M |
| Cost of Revenue | — | — | $0 | $518.0K | $938.0K | $528.6K | $181.4K | $7.2M |
| Gross Profit | — | — | $0 | $140.5K | $259.5K | $159.4K | $12.1K | $833.4K |
| Gross Margin | — | — | — | 21.3% | 21.7% | 23.2% | 6.3% | 10.4% |
| Operating Expenses | ||||||||
| Research & Development | — | $0 | $4.8M | $10.1M | $5.3M | — | — | — |
| SG&A Expense | $154.0K | $38.0K | $3.5M | $5.9M | $2.7M | $289.9K | $434.8K | $317.9K |
| Operating Income | $-154.0K | $-38.0K | $-8.8M | $-15.9M | $-7.7M | $-130.5K | $-422.8K | $515.6K |
| Operating Margin | — | — | — | -2,410.0% | -642.5% | -19.0% | -218.4% | 6.4% |
| Interest Expense | — | — | $3.2K | $1.7K | $893 | $1.1K | — | — |
| Pretax Income | $-101.1K | $-42.3K | $-8.8M | $-15.9M | — | $-135.5K | $-424.7K | $511.9K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $-18.1K | $-53.1K | $92.2K |
| Net Income | $-101.1K | $-42.3K | $-8.8M | $-15.9M | $-7.7M | $-117.5K | $-371.6K | $419.7K |
| Net Margin | — | — | — | -2,410.2% | -642.8% | -17.1% | -192.0% | 5.2% |
| EPS (Basic) | — | — | — | — | $-0.14 | $0.00 | $-0.01 | $0.01 |
| EPS (Diluted) | $0.00 | $0.00 | $-0.15 | $-0.26 | — | $0.00 | $-0.01 | $0.01 |
| Shares Outstanding (Basic) | — | — | — | — | — | — | 47.8M | 47.8M |
| Shares Outstanding (Diluted) | 60.0M | 60.0M | 60.0M | 60.0M | 53.8M | 47.8M | 47.8M | 47.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |